The July International Casualty Reinsurance Panel featured a detailed presentation from Exona Lab on emerging AI-related insurance risks. Real-world examples included AI-driven bodily injury claims, failures in safety systems, biased hiring tools, privacy breaches, medical advice errors and emergency alert failures. Members explored how AI-related liability is increasingly being assessed through product liability principles and noted the absence of established insurance products or pricing frameworks for these risks. The discussion emphasised the need for dedicated AI risk assessment tools and exposure management capabilities. Panel members also noted leadership changes, with an interim chair appointed following a departure from the market. Progress continued on legacy wording reviews, particularly modernisation of ACOD clauses and alignment with communicable disease wording. Broader market updates included developments in PFAS and contaminant litigation, ultra-processed foods claims, rising UK defence costs, Australian shareholder class actions and Lloyd’s review of medical malpractice business. Non-marine committee updates covered AI definitions, digital asset clauses and broker-led governing law wording issues.